On April 24, 2026, the World Health Organization announced the approval of the first malaria drug designed for infants, marking a pivotal moment in the fight against the disease.
This new medication targets children under five, who represent a staggering two-thirds of malaria-related deaths globally, highlighting the urgent need for effective treatments in this age group.
Health experts anticipate that this drug could lead to a substantial decrease in malaria fatalities among young children, offering renewed hope for families and communities affected by the disease.